San Francisco—A new pilot study suggests that pharmacogenomics (PGx) testing may help clinicians avoid toxicities in patients with colorectal cancer, paving the way for such testing in other settings to help optimize treatment and avoid adverse effects.
“Our pilot study also showed that when we have the right players involved, including pharmacist experts who can offer patient-specific recommendations and follow-up, we make more meaningful use of the comprehensive